Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Congress skips patent bill to hurry home

WASHINGTON - The House adjourned Saturday without taking action on a biotechnology patent bill, ensuring that the Congress will not pass the legislation this year.

The proposed process patent law would overrule the application of a Federal Circuit Court decision, made in the "Durden" case, to biological process patents. In Durden, the court had ruled that when a chemical process, such

Read the full 602 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE